Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos

Background Losartan is widely used in many clinicals settings. Its dosage is related to the genetic characteristics of CYP2C9 enzymatic activity, which metabolizes losartan to its active form E-3174, responsible for the antihypertensive effect. Aims To identify the frequency of allelic variants CYP2C9*2 and CYP2C9*3 in hypertensive patients and to compare genotypes with a healthy Chilean population. To relate polymorphisms with the losartan dosing to obtain an optimal blood pressure. Material and Methods We studied 30 patients with controlled essential hypertension using losartan with normal liver function, and 202 healthy people. Peripheral blood DNA genotyping was performed by polymerase chain reaction to identify the polymorphisms. Allelic and genotypic frequencies were compared. Results In hypertensive patients, allelic frequencies were 0.85 (CYP2C9*1), 0.05 (CYP2C9*2) and 0.1 (CYP2C9*3). Genotypic frequencies were 73.3% (CYP2C9*1/*1), 6.7% (CYP2C9*1/*2), 16.7% (CYP2C9*1/*3) and 3.3% (CYP2C9*2/3); observing a significantly higher frequency of the allele CYP2C9*3 (p=0.041) and CYP2C9*1/*3 genotype (p=0.04). A non-significant tendency to need a larger dose of losartan was observed with the CYP2C9 * 3 allele, with an odds ratio (OR) of 1.46 (95% confidence intervals (CI) 0.01-18.64). The same tendency was observed with the need to use losartan twice a day, obtaining an OR of 5.88 (CI 0.54 -62.14). Conclusions There could be a relationship between the presence of CYP2C9 polymorphisms and the pathogenesis of hypertension. The presence of CYP2C9*3 is associated with the need for higher doses of losartan, possibly due to a decrease in the conversion of losartan to E-3174.

Saved in:
Bibliographic Details
Main Authors: PEDREROS-ROSALES,CRISTIAN, JALIL MILAD,ROBERTO, LAGOS LUCERO,MARCELA, SOLARI GAJARDO,SANDRA
Format: Digital revista
Language:Spanish / Castilian
Published: Sociedad Médica de Santiago 2019
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201527
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0034-98872019001201527
record_format ojs
spelling oai:scielo:S0034-988720190012015272020-07-22Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenosPEDREROS-ROSALES,CRISTIANJALIL MILAD,ROBERTOLAGOS LUCERO,MARCELASOLARI GAJARDO,SANDRA Cytochrome P-450 CYP2C9 Genotype Losartan Polimorphism, Genetic Background Losartan is widely used in many clinicals settings. Its dosage is related to the genetic characteristics of CYP2C9 enzymatic activity, which metabolizes losartan to its active form E-3174, responsible for the antihypertensive effect. Aims To identify the frequency of allelic variants CYP2C9*2 and CYP2C9*3 in hypertensive patients and to compare genotypes with a healthy Chilean population. To relate polymorphisms with the losartan dosing to obtain an optimal blood pressure. Material and Methods We studied 30 patients with controlled essential hypertension using losartan with normal liver function, and 202 healthy people. Peripheral blood DNA genotyping was performed by polymerase chain reaction to identify the polymorphisms. Allelic and genotypic frequencies were compared. Results In hypertensive patients, allelic frequencies were 0.85 (CYP2C9*1), 0.05 (CYP2C9*2) and 0.1 (CYP2C9*3). Genotypic frequencies were 73.3% (CYP2C9*1/*1), 6.7% (CYP2C9*1/*2), 16.7% (CYP2C9*1/*3) and 3.3% (CYP2C9*2/3); observing a significantly higher frequency of the allele CYP2C9*3 (p=0.041) and CYP2C9*1/*3 genotype (p=0.04). A non-significant tendency to need a larger dose of losartan was observed with the CYP2C9 * 3 allele, with an odds ratio (OR) of 1.46 (95% confidence intervals (CI) 0.01-18.64). The same tendency was observed with the need to use losartan twice a day, obtaining an OR of 5.88 (CI 0.54 -62.14). Conclusions There could be a relationship between the presence of CYP2C9 polymorphisms and the pathogenesis of hypertension. The presence of CYP2C9*3 is associated with the need for higher doses of losartan, possibly due to a decrease in the conversion of losartan to E-3174.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.12 20192019-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201527es10.4067/S0034-98872019001201527
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language Spanish / Castilian
format Digital
author PEDREROS-ROSALES,CRISTIAN
JALIL MILAD,ROBERTO
LAGOS LUCERO,MARCELA
SOLARI GAJARDO,SANDRA
spellingShingle PEDREROS-ROSALES,CRISTIAN
JALIL MILAD,ROBERTO
LAGOS LUCERO,MARCELA
SOLARI GAJARDO,SANDRA
Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos
author_facet PEDREROS-ROSALES,CRISTIAN
JALIL MILAD,ROBERTO
LAGOS LUCERO,MARCELA
SOLARI GAJARDO,SANDRA
author_sort PEDREROS-ROSALES,CRISTIAN
title Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos
title_short Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos
title_full Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos
title_fullStr Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos
title_full_unstemmed Efecto de las variantes de CYP2C9 sobre la dosis de losartán en hipertensos chilenos
title_sort efecto de las variantes de cyp2c9 sobre la dosis de losartán en hipertensos chilenos
description Background Losartan is widely used in many clinicals settings. Its dosage is related to the genetic characteristics of CYP2C9 enzymatic activity, which metabolizes losartan to its active form E-3174, responsible for the antihypertensive effect. Aims To identify the frequency of allelic variants CYP2C9*2 and CYP2C9*3 in hypertensive patients and to compare genotypes with a healthy Chilean population. To relate polymorphisms with the losartan dosing to obtain an optimal blood pressure. Material and Methods We studied 30 patients with controlled essential hypertension using losartan with normal liver function, and 202 healthy people. Peripheral blood DNA genotyping was performed by polymerase chain reaction to identify the polymorphisms. Allelic and genotypic frequencies were compared. Results In hypertensive patients, allelic frequencies were 0.85 (CYP2C9*1), 0.05 (CYP2C9*2) and 0.1 (CYP2C9*3). Genotypic frequencies were 73.3% (CYP2C9*1/*1), 6.7% (CYP2C9*1/*2), 16.7% (CYP2C9*1/*3) and 3.3% (CYP2C9*2/3); observing a significantly higher frequency of the allele CYP2C9*3 (p=0.041) and CYP2C9*1/*3 genotype (p=0.04). A non-significant tendency to need a larger dose of losartan was observed with the CYP2C9 * 3 allele, with an odds ratio (OR) of 1.46 (95% confidence intervals (CI) 0.01-18.64). The same tendency was observed with the need to use losartan twice a day, obtaining an OR of 5.88 (CI 0.54 -62.14). Conclusions There could be a relationship between the presence of CYP2C9 polymorphisms and the pathogenesis of hypertension. The presence of CYP2C9*3 is associated with the need for higher doses of losartan, possibly due to a decrease in the conversion of losartan to E-3174.
publisher Sociedad Médica de Santiago
publishDate 2019
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019001201527
work_keys_str_mv AT pedrerosrosalescristian efectodelasvariantesdecyp2c9sobreladosisdelosartanenhipertensoschilenos
AT jalilmiladroberto efectodelasvariantesdecyp2c9sobreladosisdelosartanenhipertensoschilenos
AT lagosluceromarcela efectodelasvariantesdecyp2c9sobreladosisdelosartanenhipertensoschilenos
AT solarigajardosandra efectodelasvariantesdecyp2c9sobreladosisdelosartanenhipertensoschilenos
_version_ 1755988634821984256